NZYM B Novozymes A/S Class B

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program

Please read the announcement in PDF

Attachment



EN
19/05/2025

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Combining EVP roles of Human Health Biosolutions and Strategy & Integr...

Combining EVP roles of Human Health Biosolutions and Strategy & Integration As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration.  COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy & Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vi...

10h / 16m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

10h / 25m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

May 12, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the announcement in PDF Attachment

May 12, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis delivered a strong Q1 with 11% organic growth and confirms f...

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, say...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch